靶向成纤维细胞生长因子受体2在胃癌中的研究:希望还是陷阱?
胃癌是全球癌症第三大死因,系统性化疗仍是主要治疗选择,曲妥珠单抗是唯一获批用于HER2阳性胃癌的靶向药物。成纤维细胞生长因子受体(FGFR)通路在胃癌发病中起关键作用,1.2%-9%的胃癌患者存在FGFR2扩增,多种选择性FGFR抑制剂已显示出有希望的疗效信号,但可靠的疗效预测生物标志物证据仍稀缺。
要点
- 胃癌中1.2%-9%的患者存在FGFR2扩增,FGFR通路在发病中起关键作用。
- 多种选择性FGFR抑制剂已开发并显示有希望的疗效信号。
- 均一高水平克隆性FGFR2扩增等被认为是潜在的FGFR抑制疗效预测标志物。
核心结论
- 胃癌靶向FGFR2的研究取得一定进展,多种选择性FGFR抑制剂显示出有希望的疗效信号,但最可靠的疗效预测生物标志物证据仍稀缺。
- 高特异性FGFR抑制剂的成功开发有赖于基于对胃癌关键驱动改变更深入认识而建立新的个体化策略。
- 在FGFR抑制剂开发的下一阶段,实施准确的预测生物标志物似乎势在必行。
研究设计与样本
- 本文为综述,围绕胃癌中靶向成纤维细胞生长因子受体2(FGFR2)的相关证据进行汇总与讨论。
主要发现
- 胃癌是全球癌症第三大死因,系统性化疗仍是这一预后不良癌症的主要治疗选择。
- 曲妥珠单抗是唯一获批用于分子标志物选择的HER2阳性胃癌患者的生物制剂。
- 1.2%-9%的胃癌患者存在FGFR2扩增。
- 均一高水平克隆性FGFR2扩增、高FGFR2 mRNA或蛋白水平、特定FGFR2 C3异构体表达、FGF配体共过表达或血浆循环肿瘤DNA中检测FGFR2拷贝数,被认为是FGFR抑制的潜在预测生物标志物。
局限性
- 对这些靶向药物疗效的最可靠分子决定因素证据仍稀缺。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gastric cancer is the third leading cause of death from cancer worldwide. Systemic chemotherapy remains the mainstay therapeutic option for this poor prognosis cancer. Trastuzumab, the epidermal growth factor receptor 2 (ERBB2 or HER2)-antibody, is the only biological agent approved for the molecularly selected population of HER2-positive gastric cancer patients. Over the last decade, several groups have been working for deepening into the molecular characterization of gastric cancer, shedding some light into the heterogeneity of this tumour. The published data have broadened the landscape towards a future molecular classification into several subtypes of gastric cancer, enabling a better selection of the optimal therapeutic strategy. The fibroblast growth factor receptor (FGFR) pathway plays a key role in gastric cancer pathogenesis, with 1.2%-9% of gastric cancer patients harbouring FGFR2 amplifications. Several selective FGFR inhibitors have been developed in the last years, with promising efficacy signals. However, there is still scarce evidence of the most reliant molecular determinants of response to these targeted agents. Homogeneous high-level clonal FGFR2-amplification, high FGFR2 mRNA or protein levels, specific FGFR2 C3 isoform expression, FGF ligand co-overexpression or detection of FGFR2 copy number in plasma circulating tumour DNA, are considered some of the potential predictive biomarkers to the FGFR inhibition. The successful development of highly specific FGFR inhibitors will rely on our capacity of establishing new personalized strategies, based on a deeper knowledge of the key alterations that drive oncogenesis in gastric cancer. Further efforts seem mandatory in order to implement accurate predictive biomarkers in the next stages of the FGFR inhibitors development.
引用
- Hierro C, Alsina M, Sánchez M, et al. Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall? Ann Oncol. 2017. PMID: 28327938. doi:10.1093/annonc/mdx081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。